AVTR · NYSE · STOCK
Avantor (AVTR) Stock Analysis
$15.67
52W $7.26 – $16.38
59/100
$10.60B
-18.7
0.94
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is AVTR Bullish or Bearish?
Bullish.
Innellis AI committee rates Avantor (AVTR) Buy with a composite score of 59/100
, based on 5 analysts with 60% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +16.39 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -3.61 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Price-to-book of 1.4x is a discount to asset value — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- News sentiment is positive (+0.22 across 9 articles, 14d) — News
Bear Case
- ROE of only -10.3% -- cheap may mean cheap for a reason — Value
- Revenue declining -1.6% YoY -- this is not a growth story right now — Growth
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 85 -- overbought on the larger timeframe too — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
59/100
Agreement
60%
Analysts
5
Conviction
Moderate
Sector Rank
Top 41%
of 192 Healthcare peers
Value Analyst
neutral
55
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
+ Price-to-book of 1.4x is a discount to asset value
− ROE of only -10.3% -- cheap may mean cheap for a reason
Growth Analyst
neutral
50
/ 100 · Moderate confidence
Moderate growth -- present but not remarkable
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
− Revenue declining -1.6% YoY -- this is not a growth story right now
Technical Analyst
neutral
58
/ 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
65
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.22 across 9 articles, 14d)
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 58.6 to 58.6.
- New bearish signals: 1 appeared.
- Bearish pressure eased: 1 signal(s) disappeared.
Analyst-level changes:
- Technical Analyst: +1 bearish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
61.8
Neutral
MACD Histogram
-0.033
Bearish Momentum
Trend Direction
Uptrend
Weekly: Sideways
Market Structure
Hh Hl
Support
$15.38
Resistance
$15.90
Bollinger %B
0.81
Inside Bands
Price vs Moving Averages
EMA 9
$15.41
Above
EMA 21
$15.22
Above
EMA 50
$14.36
Above
EMA 200
$12.21
Above
Fundamental Analysis
Valuation
98
Growth
57
Profitability
7
Financial Health
87
Cash Flow
70
Valuation
P/E Ratio
-18.7×
P/B Ratio
1.88×
PEG Ratio
0.37
Dividend Yield
0.00%
52W High
$16.38
52W Low
$7.26
Quality & Growth
ROE
-952.7%
ROA
-449.5%
Gross Margin
3182.6%
Operating Margin
-435.3%
Revenue Growth YoY
—
Debt / Equity
0.66
AI Fundamental Assessment
P/E ratio of -18.7 (inexpensive relative to a 15-40x range); Price-to-book of 1.9x; PEG ratio of 0.4 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -9.5%; Return on assets of -4.5%; Net margin of -8.8%; Gross margin of 31.8%; Current ratio of 1.78 (healthy short-term liquidity); Debt-to-equity of 0.66; Free cash flow per share is positive (0.67); Most recent quarter beat estimates by 8.6%; 2 consecutive earnings beats; EPS growth accelerating (-22.7% -> +23.5% QoQ); Average YoY EPS growth of -12.5%; Analyst estimates falling over recent quarters
Get the Full AVTR Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →